Chimerix (NASDAQ:CMRX) Share Price Passes Below Two Hundred Day Moving Average – What’s Next?

Chimerix, Inc. (NASDAQ:CMRX) shares passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.91 and traded as low as $0.84. Chimerix shares last traded at $0.87, with a volume of 163,138 shares trading hands.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on CMRX shares. Wedbush reiterated an “outperform” rating and set a $6.00 price objective on shares of Chimerix in a research report on Tuesday, August 13th. HC Wainwright reissued a “buy” rating and issued a $11.00 price target on shares of Chimerix in a research note on Wednesday, August 14th. Finally, StockNews.com raised Chimerix from a “sell” rating to a “hold” rating in a report on Wednesday, August 21st.

Chimerix Stock Performance

The business’s 50 day moving average price is $0.91 and its two-hundred day moving average price is $0.91. The company has a market capitalization of $77.98 million, a price-to-earnings ratio of -0.94 and a beta of 1.12.

Chimerix (NASDAQ:CMRX) last released its earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.23). The firm had revenue of $0.13 million during the quarter, compared to analyst estimates of $1.26 million. During the same quarter last year, the company earned ($0.21) earnings per share. On average, sell-side analysts expect that Chimerix, Inc. will post -0.86 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of CMRX. Koshinski Asset Management Inc. bought a new stake in Chimerix in the first quarter worth about $42,000. Valeo Financial Advisors LLC raised its holdings in shares of Chimerix by 566.9% in the 3rd quarter. Valeo Financial Advisors LLC now owns 81,766 shares of the biopharmaceutical company’s stock worth $76,000 after purchasing an additional 69,505 shares in the last quarter. Marquette Asset Management LLC lifted its stake in Chimerix by 24.3% during the first quarter. Marquette Asset Management LLC now owns 116,009 shares of the biopharmaceutical company’s stock valued at $123,000 after purchasing an additional 22,709 shares during the last quarter. Marshall Wace LLP bought a new stake in Chimerix during the second quarter worth approximately $137,000. Finally, Acadian Asset Management LLC grew its position in Chimerix by 15.5% in the first quarter. Acadian Asset Management LLC now owns 2,174,813 shares of the biopharmaceutical company’s stock worth $2,304,000 after buying an additional 291,981 shares during the last quarter. Institutional investors own 45.42% of the company’s stock.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.